Title: National Clinical Care Commission Act
Policy area: Health

Summary:
National Clinical Care Commission Act
This bill establishes within the Department of Health and Human Services (HHS) a National Clinical Care Commission to evaluate and make recommendations regarding improvements to the coordination and leveraging of federal programs related to complex metabolic or autoimmune diseases that result from issues related to insulin and represent a significant disease burden (e.g., diabetes). The commission must report on: (1) HHS programs that focus on prevention, (2) current activities and gaps in federal efforts to support clinicians in providing integrated care, (3) improvement in federal education and awareness activities related to prevention and treatment, and (4) methods for outreach and dissemination of education and awareness materials.
The commission must submit an operating plan to HHS and Congress within 90 days of its first meeting. The commission is terminated after it submits a final report, but not later than the end of FY2021.

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[S. 920 Introduced in Senate (IS)]

<DOC>






115th CONGRESS
  1st Session
                                 S. 920

           To establish a National Clinical Care Commission.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                             April 24, 2017

  Mrs. Shaheen (for herself and Ms. Collins) introduced the following 
  bill; which was read twice and referred to the Committee on Health, 
                     Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL


 
           To establish a National Clinical Care Commission.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``National Clinical Care Commission 
Act''.

SEC. 2. NATIONAL CLINICAL CARE COMMISSION.

    (a) Establishment.--There is hereby established, within the 
Department of Health and Human Services, a National Clinical Care 
Commission (in this section referred to as the ``Commission'') to 
evaluate and make recommendations regarding improvements to the 
coordination and leveraging of programs within the Department and other 
Federal agencies related to awareness and clinical care for at least 
one, but not more than two, complex metabolic or autoimmune diseases 
resulting from issues related to insulin that represent a significant 
disease burden in the United States, which may include complications 
due to such diseases.
    (b) Membership.--
            (1) In general.--The Commission shall be composed of the 
        following voting members:
                    (A) The heads of the following Federal agencies and 
                departments, or their designees:
                            (i) The Centers for Medicare & Medicaid 
                        Services.
                            (ii) The Agency for Healthcare Research and 
                        Quality.
                            (iii) The Centers for Disease Control and 
                        Prevention.
                            (iv) The Indian Health Service.
                            (v) The Department of Veterans Affairs.
                            (vi) The National Institutes of Health.
                            (vii) The Food and Drug Administration.
                            (viii) The Health Resources and Services 
                        Administration.
                            (ix) The Department of Defense.
                            (x) The Department of Agriculture.
                            (xi) The Office of Minority Health.
                    (B) Twelve additional voting members appointed 
                under paragraph (2).
            (2) Additional members.--The Commission shall include 
        additional voting members, as may be appointed by the 
        Secretary, with expertise in the prevention, care, and 
        epidemiology of any of the diseases and complications described 
        in subsection (a), including one or more such members from each 
        of the following categories:
                    (A) Physician specialties, including clinical 
                endocrinologists, that play a role in the prevention or 
                treatment of diseases and complications described in 
                subsection (a).
                    (B) Primary care physicians.
                    (C) Non-physician health care professionals.
                    (D) Patient advocates.
                    (E) National experts, including public health 
                experts, in the duties listed under subsection (c).
                    (F) Health care providers furnishing services to a 
                patient population that consists of a high percentage 
                (as specified by the Secretary) of individuals who are 
                enrolled in a State plan under title XIX of the Social 
                Security Act or who are not covered under a health plan 
                or health insurance coverage.
            (3) Chairperson.--The members of the Commission shall 
        select a chairperson from the members appointed under paragraph 
        (2).
            (4) Meetings.--The Commission shall meet at least twice, 
        and not more than four times, a year.
            (5) Vacancies.--A vacancy on the Commission shall be filled 
        in the same manner as the original appointments.
    (c) Duties.--The Commission shall evaluate and make 
recommendations, as appropriate, to the Secretary of Health and Human 
Services and Congress regarding--
            (1) Federal programs of the Department of Health and Human 
        Services that focus on preventing and reducing the incidence of 
        the diseases and complications described in subsection (a);
            (2) current activities and gaps in Federal efforts to 
        support clinicians in providing integrated, high-quality care 
        to individuals with the diseases and complications described in 
        subsection (a);
            (3) the improvement in, and improved coordination of, 
        Federal education and awareness activities related to the 
        prevention and treatment of the diseases and complications 
        described in subsection (a), which may include the utilization 
        of new and existing technologies; and
            (4) methods for outreach and dissemination of education and 
        awareness materials that--
                    (A) address the diseases and complications 
                described in subsection (a);
                    (B) are funded by the Federal Government; and
                    (C) are intended for health care professionals and 
                the public.
    (d) Operating Plan.--Not later than 90 days after its first 
meeting, the Commission shall submit to the Secretary of Health and 
Human Services and the Congress an operating plan for carrying out the 
activities of the Commission as described in subsection (c). Such 
operating plan may include--
            (1) a list of specific activities that the Commission plans 
        to conduct for purposes of carrying out the duties described in 
        each of the paragraphs in subsection (c);
            (2) a plan for completing the activities;
            (3) a list of members of the Commission and other 
        individuals who are not members of the Commission who will need 
        to be involved to conduct such activities;
            (4) an explanation of Federal agency involvement and 
        coordination needed to conduct such activities;
            (5) a budget for conducting such activities; and
            (6) other information that the Commission deems 
        appropriate.
    (e) Final Report.--By not later than 3 years after the date of the 
Commission's first meeting, the Commission shall submit to the 
Secretary of Health and Human Services and the Congress a final report 
containing all of the findings and recommendations required by this 
section.
    (f) Sunset.--The Commission shall terminate 60 days after 
submitting its final report, but not later than the end of fiscal year 
2021.
                                 <all>